Home/Pipeline/UPNEEQ® (oxymetazoline) Mini

UPNEEQ® (oxymetazoline) Mini

Acquired Blepharoptosis

MarketedLaunched (Japan, 2026)

Key Facts

Indication
Acquired Blepharoptosis
Phase
Marketed
Status
Launched (Japan, 2026)
Company

About santen

Santen Pharmaceutical Co., Ltd. is a leading global ophthalmology company founded in 1890 with a mission to achieve 'Happiness with Vision.' The company has built a fully integrated business model spanning R&D, manufacturing, and commercialization, serving patients in over 60 countries. Its strategy is centered on deepening its ophthalmic expertise, expanding its portfolio through internal innovation and strategic partnerships, and aiming to become the most trusted global ophthalmology company by 2035.

View full company profile

Other Acquired Blepharoptosis Drugs

DrugCompanyPhase
LEV-102Levation PharmaPhase 1/2